Sanofi's Diabetes Drug Toujeo Gets U.S. ApprovalSanofi's Diabetes Drug Toujeo Gets U.S. Approval

The U.S. Food and Drug Administration (FDA) has approved Sanofi's new once-daily long-acting basal insulin Toujeo (insulin glargine 300 U/mL). Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news